Genetic testing and prevention of hereditary cancer at the MMCI - Over 10 years of experience

Klinicka Onkologie

Volumn 23, Issue 6, 2010, Pages 388-400

  Foretova, L ^a   Petrakova, K ^a   Palacova, M ^a   Kalabova, R ^a   Svoboda, M ^a   Navratilova, M ^a   Schneiderova, M ^a   Bolcak, K ^a   Krejci, E ^a   Drazan, L ^b   Mikova, M ^a   Hazova, J ^a   Vasickova, P ^a   Machackova, E ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Genes; Genetic testing; Hereditary cancer; Prevention; Syndromes

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

BREAST CANCER; CANCER PREVENTION; COLORECTAL CANCER; CZECH REPUBLIC; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; HEALTH INSURANCE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; MUTATIONAL ANALYSIS; OVARY CANCER; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PEDIGREE;

EID: 78650664925     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Dusek L et al. Czech Cancer Care In Numbers 2009-2009. Praha: Grada 2009: 153.
2. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36(11): 801-818.
3. Lynch HT, Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 2000;18(Suppl):19S-31S.
4. Lynch HT, Smyrk TC, Watson P et al. Genetics, natural history, tumor spectrum and patology of hereditary non-polyposis colorectal cancer: an updated review. Gastroenterology 1993; 104:1535-1549.
5. Lynch HT, Chapelle A. Hereditary colorectal cancer. N Eng J Med 2003; 348(10): 919-932.
6. Miki Y, Swensen J, Shattuck-Eldens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene. Science 1994; 266(5182): 66-71.
7. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559): 789-792.
8. Friend SH, Bernards R, Rogelj S. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarkoma. Nature 1986; 323(6089): 643-646.
9. Li FP, Correa P, Fraumeni JF jr. Testing for germline p53 mutations in cancer families. Cancer Epidemiol Biomark Prev 1991; 1:91-94.
10. Srivastava S, Zou Z, Pirrollo K et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348(6303): 747-749.
11. Goetz P, Foretova L, Puchmajerova A. Hereditary aetiology of cancer diseases and the importance of genetic counselling and testing in oncology. Klin Onkol 2006; 19 (Suppl)-44-48
12. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23(2): 276-292
13. Foretová L, Petráková K, Palácová M et al. Genetic and preventive services for hereditary breast and ovarian cancer in the Czech Republic. Hereditary Cancer in Clinical Practice 2006; 4(1): 3-6.
14. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62(3): 676-689.
15. Shulman LP. Hereditary breast and ovarian cancer (HBOC): Clinical features and Counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li.-Fraumeni. Obstet Gynecol Clin N Am 2010; 37(1): 109-133.
16. Bosch A, Eroles P, Zaragoza R et al. Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews 2010; 36(3): 206-215.
17. Stead LA, Lash TL, Sobieraj JE et al Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Research 2009; 11:R18.
18. Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl J Med 2010; 363(20)-1938-1948.
19. de Ruijter TC, Veeck J, de Hoon JP et al. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2010 [Epub ahead of print].
20. Bartoňková H, Foretová L, Helmichová E et al. The recommendation of clinical care for patients with breast and ovarian cancer and for healthy people with germline mutations In BRCA] and BRCA2 genes. KIm Onkol 2003; 16(1): 28-34.
21. Plevová P, Novotný J, Petráková K et al. Syndrom hereditárního karcinomu prsu a ovarií. Klin Onkol 2009 (Suppl S1):S6-S11.
22. Mateju J, Stribrna M, Zikan M et al. Population based study of BRCA 1/2 mutations: family history based criteria identify minority of mutation carriers. Neoplasma 2010; 57(3): 280-285.
23. Cybulski C, Górskl T, Huzarski T et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75(6):1131-1135.
24. The CHEK2 Breast Cancer Case-Control Consortium. CHEK2 1100delC and susceptibility to breast cancer. a collaborative analysis involving 10, 860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74(6): 1175-1182.
25. Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 In families at high risk of breast cancer. JAMA 2006; 295(12): 1379-1388.
26. Machackova E, Foretova L, Lukesova M et al. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 2008, 8(140): 12.
27. Stoep N, Paridon Ch, Janssens T et al Diagnostic guidelines for High-Resolution Melting curve (HRM) analysis: A validation of BRCA1 mutation scanning using the 96-well LightScanner. Human Mutation 2009; 30(6): 899-909.
28. Foretova L, Machackova E, Navratilova M et al. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Human Mutation 2004; 23(4): 397-398.
29. Vasickova P, Machackova E, Lukesova M et al. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet 2007; 8:32.
30. Hucl T, Rago C, Gallmeier E et al. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 2008; 68(13): 5023-5030.
31. Kleibl Z, Novotny J, Bezdickova D et al. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Research and Treatment 2005; 90(2): 165-167.
32. Schneiderova M, Belanova R, Lidakova J et al. Magnetic resonance of breast as a screening method In women with high risk of breast cancer. Educational Proceedings. BOD 2009:91-92.
33. Schneiderova M, Bartonkova H. Breast magnetic resonance imaging in surveillance of women at high risk for breast cancer. Klin Onkol 2006; 19 (Suppl): 91-96.
34. Evans DG, Shenton A, Woodward E. Penetrance estimated for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: Risk of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8:155.
35. Blanchard DK, Hartmann LC. Prophylactic surgery for women at high risk for breast cancer. Clin Breast Cancer 2000; 1(2): 127-134.
36. Eisen A Rebbeck TR, Wood WC et al. Prophylactic Surgery in Women With a Hereditary Predisposition to Breast and Ovarian Cancer 2000; J Clin Oncol 2000; 18(9): 1980-1995.
37. Hughes KS, Papa MZ, Whitney T et al. Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer Supplement 1999; 86:2502-2515.
38. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM et al. Presymptomatic DNA testing and prophylactic surgery In families with a BRCA1 or BRCA2 mutation. Lancet 2000; 355(9220): 2015-2020.
39. Meijers-Heijboer H, van Geel B, van Putten WU et al. Breast cancer after prophylactic bilateral mastectomy In women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-163.
40. Drazan L Prophylactic mastectomy and its Indications In high-risk women Klin Onkol 2006; 19 (Suppl): 97-100.
41. Dražan L, Hýža R Stupka I et al. Oboustranná rekonstrukce prsů dvěma DIEP laloky: Jak ji hodnoti pacientky? Praktický lékař 2009; 89(6): 306-311.
42. Ivanovich JL, Reed TE, Ciske DJ et al. A practical approach to familial and hereditary colorectal cancer. Am J Med 1999; 107(1)-68-77.
43. Křepelová A, Pavlíková K, Plevová R Diagnostika Lynchova syndromu - nové geny a metody. Klin Onkol 2006; 19 (Suppl): 76-81.
44. Plevová P, Novotný J, Šachlová M et al. Hereditární nepolypózní kolorektální karcinom (HNPCC, Lynchův syndrom). Klin Onkol 2009; (Suppl S1): S12-S15.
45. Hisada M, Garber JE, Fung CY et al. Multiple primary cancers in familles with Li-Fraumenl syndrome. J Natl Cancer Inst 1998; 90(8)- 606-611.
46. Krutílková V, Trková M, Kodet R et al. Syndrom Li-Fraumeni. Čs pediatrie 2003; 58(9): 552-555.
47. Foretová L, Navrátilová M, Petrákova K. Kasuistiky Li-Fraumeni syndromu: diagnostické a preventivní možnosti. Klin Onkol 2006; 19 (Suppl): 85-87
48. Plevová P, Krutílková V, Petráková K et al. Syndrom Li-Fraumeni. Klim Onkol 2009; (Suppl S1): S20-S22.
49. Foretová L, Macháčková E, Šachlová M et al. Syndrom familiárního melanomu (s dysplastickými naevy či bez nich). Kim Onkol 2009; (Suppl S1): S32-S33.
50. Hodgson SV, Foulkes WD, Eng CH et al. A practical guide to human cancer genetics. 3rd ed. Cambridge University Press, 2007.
51. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Human Molecular Genetics 2001, 10(7): 721-733.
52. Plevová P, Štekrová J, Kohoutová M et al. Familiární adenomatózní polypóza. Klin Onkol 2009 (Suppl S1)- S16-S19.
53. Giardiello FM, Brenslnger JD, Tersmett AC et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119(6): 1447-1453.
54. Ivanovich JF, whelan AJ. Cancer and Peutz-Jeghers Syndrome, a Review. Journal of Genetic Counseling 1997; 6(2): 193-206.
55. Morak M, Laner A, Bacher U et al. MUTYH-associated polyposls-variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. Clim Genet 2010; 78(4): 353-363.
56. Stadler ZK, Vijai J, Thom P et al Genome-wide association studies of cancer predisposition. Hematol Oncol Clin N Am 2010; 24:973-996.
57. Robson M, Offit K. Inherited predisposition to cancer. Introduction and overview. Hematol Oncol Clin N Am 2010, 24(5):793-797.
58. Ripperger T, Gadzicki D, Meindl A et al. Breast cancer susceptibility: current knowledge and implications for genetic counselling Eur J Hum Genet 2009; 17(6): 722-731.